Takeda may have pruned back the potential indications for mezagitamab, but the latest raft of phase 2 data suggests the anti-CD38 antibody could still “transform treatment” of primary immune ...
NEW ORLEANS — Efgartigimod demonstrated clinically significant improvement in platelet counts compared with placebo among adults with primary immune thrombocytopenia, results of the phase 3 ADVANCE IV ...
Q: My platelets were slightly elevated on my blood test. What can cause this? A: Platelets are part of how our body forms clots to stop bleeding. They are produced in the bone marrow by cells called ...
SAN DIEGO — Phase 3 data support rilzabrutinib as a potential first-in-class oral Bruton tyrosine kinase (BTK) inhibitor for patients with previously treated immune thrombocytopenia (ITP). In the LUNA ...
Promacta tended to boost platelet counts in patients with low-risk MDS, and helped those patients be independent of transfusions, too. Promacta (eltrombopag) improved platelet counts in patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback